Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel
Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse
 over time, but how quickly it progresses varies a lot from person to person. Some symptoms of
 PD are tremors, stiffness, and slowness of movement. The purpose of this study is to see how
 feasible and how satisfied participants/caregivers/investigators are with video-assisted
 telenursing use in nurse support programs with LCIG.

 LCIG is an approved drug to treat PD. Approximately 50 adult participants with advanced PD
 will be enrolled in the study at approximately 10 sites across the world.

 The study has 2 groups. In one group, around 25 participants will receive nurse support using
 video devices. In the second group, around 25 participants will receive nurse support without
 using video devices. All participants will attend a baseline visit and follow up visits at
 Week 4 and Week 12. The planned observation period will be 12 weeks.

 Participants who are prescribed LCIG by their physicians will have three study related
 visits. Participants, caregivers, and investigators will be asked to complete questionnaires
 for the study.
Inclusion Criteria:

 -  Eligible for Levodopa-Carbidopa Intestinal Gel (LCIG) therapy in accordance with the
 approved local LCIG label in the participating country

 -  Formerly LCIG-naive participants who have completed an in-hospital titration, have a
 Percutaneous Endoscopic transGastric Jejunostomy (PEG-J) placed and are discharged
 from hospital

 -  Decision to treat with LCIG made by the investigator prior to any decision to approach
 the participant to participate in this study

 -  Owns a telecommunication device equipped for videoconferencing (smart phone, tablet,
 laptop)

 -  Willing and able (based on investigator's judgment) to handle the video functionality
 of the device

 -  Caregiver willing to provide written informed consent

 Exclusion Criteria:

 -  Any condition included in the contraindications section of the approved local LCIG
 label in the participating country

 -  Lack of caregiver support

 -  Participation in a concurrent interventional clinical trial

 -  Lack of motivation or insufficient language skills to complete the study
 questionnaires